Cargando…

Study on chemotherapeutic sensitizing effect of nimotuzumab on different human esophageal squamous carcinoma cells

Esophageal cancer is one of the leading causes of mortality worldwide. Although, surgery, radio- and chemotherapy are used to treat the disease, the identification of new drugs is crucial to increase the curative effect. The aim of the present study was to examine the chemotherapeutic sensitizing ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	YANG, XIAOYU, JI, YINGHUA, KANG, XIAOCHUN, CHEN, MEILING, KOU, WEIZHENG, JIN, CAILING, LU, PING
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734185/ https://www.ncbi.nlm.nih.gov/pubmed/26893678 http://dx.doi.org/10.3892/ol.2015.3989

Ejemplares similares

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
por: Zhao, Lei, et al.
Publicado: (2012)

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing
por: Sun, Dantong, et al.
Publicado: (2020)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Thai Hoa, Nguyen Thi, et al.
Publicado: (2020)

Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma
por: Si, Xiaoyan, et al.
Publicado: (2018)

Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer
por: Han, Xinghua, et al.
Publicado: (2017)

The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study
por: Hu, Jing, et al.
Publicado: (2022)

Clinical use of tumor biomarkers in prediction for prognosis and chemotherapeutic effect in esophageal squamous cell carcinoma
por: Yang, Yuchong, et al.
Publicado: (2019)

Immunoscore Signature Predicts Postoperative Survival and Adjuvant Chemotherapeutic Benefits in Esophageal Squamous Cell Carcinoma
por: Zhuge, Lingdun, et al.
Publicado: (2020)

Predicting Tumor Sensitivity to Chemotherapeutic Drugs in Oral Squamous Cell Carcinoma Patients
por: Robert, Beaulah Mary, et al.
Publicado: (2018)

Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial
por: Lu, Ming, et al.
Publicado: (2016)

Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial
por: Liang, Jun, et al.
Publicado: (2013)

Targeting CDC7 improves sensitivity to chemotherapy of esophageal squamous cell carcinoma
por: Cao, Ji-Xiang, et al.
Publicado: (2018)

Orbital Metastasis of Esophageal Squamous Cell Carcinoma
por: Iimori, Kei, et al.
Publicado: (2020)

Profile of nimotuzumab in the treatment of high-grade glioma
por: Yang, Qun-ying, et al.
Publicado: (2015)

Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma
por: Zong, Jing-Feng, et al.
Publicado: (2021)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

Bioinformatic Analysis of Hepatocellular Carcinoma Cell Lines to the Efficacy of Nimotuzumab
por: Wang, Yu, et al.
Publicado: (2021)

Induction chemotherapy plus nimotuzumab followed by concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma
por: Song, Xinmao, et al.
Publicado: (2019)

Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma
por: Yang, Hong, et al.
Publicado: (2015)

High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy
por: Wang, Chunyu, et al.
Publicado: (2015)

Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study
por: Kato, Ken, et al.
Publicado: (2018)

Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial
por: Yang, Xu, et al.
Publicado: (2021)

Nimotuzumab Combined With Irradiation Enhances the Inhibition to the HPV16 E6-Promoted Growth of Cervical Squamous Cell Carcinoma
por: Xu, Zhonghua, et al.
Publicado: (2020)

MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab
por: Zhang, Kai-Liang, et al.
Publicado: (2014)

Nimotuzumab for COVID-19: case series
por: Abdo Cuza, Anselmo A, et al.
Publicado: (2021)

Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma
por: Yao, Ji-Jin, et al.
Publicado: (2018)

Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma
por: Li, Zhanzhan, et al.
Publicado: (2017)

Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells
por: Huang, Jianfeng, et al.
Publicado: (2018)

Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation
por: Ng, Hoi Yan, et al.
Publicado: (2018)

Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
por: Zhai, Rui-ping, et al.
Publicado: (2015)

Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence
por: Subramanian, Sundaram, et al.
Publicado: (2018)

Investigation of novel chemotherapeutics for feline oral squamous cell carcinoma
por: Piegols, Hunter John, et al.
Publicado: (2018)

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
por: Crombet Ramos, Tania, et al.
Publicado: (2020)

Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma
por: Fei, Zhaodong, et al.
Publicado: (2020)

Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: An Indian rural hospital experience
por: Rawat, Shyamji, et al.
Publicado: (2019)

Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells
por: Ding, Wen-Xiu, et al.
Publicado: (2019)

Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence
por: Subramanian, Sundaram, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_etdo9i0kssgvr3v03bsafq05r5